retatrutide effects clinical trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide vs Tirzepatide: GLP-1, GIP

Beyond appetite suppression, they modulate adipose-derived inflammatory factors, leading to reduced leptin resistance and lower levels of C-reactive protein (CRP)

Some of the common ones are: Nausea Headache Stomach pain Heartburn Dizziness Mood changes Experts say its important for people prescribed GLP-1 medications to recognize that the drugs are part of a long-term treatment plan that involves lifestyle factors such as a balanced, healthy diet and regular aerobic and strength exercise

Being weighed after a large lunch, while dehydrated from a workout, or in heavy clothing all affect the result

Response rates were strong across the board: 91.7% of participants on the 12mg dose achieved at least 10% body weight reduction